Skip to main content
OpenTrials
Completed

NCT Number: NCT05265754

The Effect of Sujok Therapy on Cancer Symptoms

The aim of this study is to determine the effect of Sujok therapy on Pain, Fatigue, Insomnia, Nausea and Vomiting experienced by patients with gastrointestinal system cancer.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Digestive System Diseases Digestive System Neoplasms Dyssomnias Fatigue Gastrointestinal Diseases Gastrointestinal Neoplasms Mental Disorders Nausea Neoplasms Neoplasms by Site Nervous System Diseases Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive Sleep Disorders, Intrinsic Sleep Initiation and Maintenance Disorders Sleep Wake Disorders Vomiting

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Atatürk Universty

Erzurum, Turkey (Türkiye)

About this study

The aim of this study is to determine the effect of Sujok treatment on Pain, Fatigue, Insomnia, Nausea and Vomiting experienced by patients with gastrointestinal system cancer. Intervention and control groups will be determined by randomization. The scales to be used in the measurement will be applied to the individuals included in the study. Then, sujok therapy will be applied to the intervention group. After 6 sessions in weeks in total, measurement tools will be applied and evaluated again.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • over 18 years old
  • Fatigue Severity Measurement - Visual Analogue Scale (VAS) fatigue score of 3 and above,
  • Pain Severity Measurement - Visual Analogue Scale (VAS) pain score of 3 and above,
  • Measurement of Nausea and Vomiting Severity - Patients with a Visual Analogue Scale (VAS) nausea and vomiting score of 3 and above will be included.

Exclusion criteria

  • Loss of sensation, amputation, injury, colostomy, etc., which will prevent practice in hands. patients will be excluded from the study.

Treatment and study plan

sujok therapy

Behavioral

sujok therapy

Primary outcomes

  1. Sujok Therapy's Positive Change in Pain Experienced by Gastrointestinal System Cancer Patients

    Time frame: 2 weeks

    To assess the pain, the MCgill Pain Scale will be applied before starting the sujok application and after the sujok applied for 2 weeks.

  2. Sujok Therapy's positive change in Fatigue Experienced by Patients with Gastrointestinal System Cancer

    Time frame: 2 weeks

    To assess the fatigue, the cancer fatigue scale will be applied before starting the sujok application and after the sujok applied for 2 weeks.

  3. Sujok Therapy's positive cahange in insomnia Experienced by Patients with Gastrointestinal System Cancer

    Time frame: 2 weeks

    In order to evaluate insomnia,the insomnia severity index will be applied before starting the sujok application and after the sujok applied for 2 weeks

  4. Sujok Therapy's positive cahange in nausea and vomiting Experienced by Patients with Gastrointestinal System Cancer

    Time frame: 2 weeks

    To evaluate nausea and vomiting, the Rhodes nausea vomiting scale will be applied before starting the sujok application and after the sujok applied for 2 weeks

Sponsors and collaborators

Lead sponsor

Ataturk University

Other

Registry information

Official study title

The Effect of Sujok Therapy on Pain, Fatigue, Insomnia, Nausea and Vomiting Experienced by Patients With Gastrointestinal System Cancer

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Mar 4, 2022
Registry last updated
Feb 24, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.